I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

Core Insights - I-Mab announced that an abstract for a combination study of givastomig, nivolumab, and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, scheduled for July 2-5 in Barcelona, Spain [1][2] Company Overview - I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment, with operations in Rockville, Maryland, and Short Hills, New Jersey [6] Product Information - Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2-positive tumor cells, designed to activate T cells through the 4-1BB signaling pathway in the tumor microenvironment [3] - Givastomig is being developed for first-line metastatic gastric cancers and has shown promising anti-tumor activity in Phase 1 trials, minimizing common toxicities associated with other 4-1BB agents [3] Clinical Study Details - The Phase 1b study is evaluating givastomig in combination with nivolumab and chemotherapy for the treatment of gastric cancer in the first-line setting, with dose escalation completed and enrollment in the first dose expansion cohort finished ahead of schedule [4] - The study builds on positive Phase 1 monotherapy data, indicating strong potential for further development [4] Partnership Information - Givastomig is being jointly developed through a global partnership with ABL Bio, with I-Mab as the lead party sharing worldwide rights, excluding Greater China and South Korea, equally with ABL Bio [5]